On June 9, Health Ministers from the 27 EU Member States unanimously signed up to a series of political commitments on behalf of Europe’s rare disease patients, by adopting a Council Recommendation on a European Action in the Field of Rare Diseases.
EuropaBio’s SME Platform has today released “Access to Finance: A Call for Action” (1), a paper highlighting problems as well as recommendations on how to tackle the issue of access to finance in the biotech industry.
Better science, better regulation and better access policies are needed in Europe to support an innovative healthcare industry and the bio-pharmaceutical industry to deliver state-of-the-art standards of prevention, treatment and cures for EU citizens.
EuropaBio, the European biotech industry association applauds the report “IB 2025: Maximising UK Opportunities from Industrial Biotechnology in a Low Carbon Economy” (1) released today by the UK’s Department for Business Enterprise and Regulatory Reform (BERR).
Taking the opportunity of the third European Patients’ Rights Day, EuropaBio, the EU Association for Bioindustries, reiterates the call to European Institutions and national governments for the involvement of patients in all EU political debates about healthcare.
In support for the second annual Rare Disease Day, EuropaBio, the European Association for Bioindustries, highlights the key role that biotechnology has for the development of treatments for rare diseases.